{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:08:00Z","timestamp":1793869680549,"version":"4.6.1"},"reference-count":142,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100019963","name":"Susan McKinnon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jid.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T17:28:24Z","timestamp":1719941304000},"page":"2364-2376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-849X","authenticated-orcid":false,"given":"Carlo Alberto","family":"Maronese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-5870","authenticated-orcid":false,"given":"Chiara","family":"Moltrasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-8319","authenticated-orcid":false,"given":"Maurizio","family":"Romagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-1366","authenticated-orcid":false,"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4609-3762","authenticated-orcid":false,"given":"Michel","family":"Gilliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.05.015_bib1","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1097\/RHU.0000000000001076","article-title":"Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment","volume":"26","author":"Abbruzzese","year":"2020","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.jid.2024.05.015_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/cup.12932","article-title":"TNF-inhibitor associated psoriatic alopecia: diagnostic utility of sebaceous lobule atrophy","volume":"44","author":"Afanasiev","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jid.2024.05.015_bib3","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1111\/ijd.16538","article-title":"Dupilumab-induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression","volume":"62","author":"Ahmad","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib117","article-title":"Dupilumab-induced scalp psoriasis in a patient with prurigo nodularis: a case report","volume":"15","author":"Al Hawsawi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2024.05.015_bib149","doi-asserted-by":"crossref","first-page":"932766","DOI":"10.3389\/fmed.2022.932766","article-title":"Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab","volume":"9","author":"Ali","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jid.2024.05.015_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000667","article-title":"Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis","volume":"4","author":"Alivernini","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jid.2024.05.015_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of paradoxical eczema in patients receiving biologics for psoriasis","volume":"160","author":"Al-Janabi","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib125","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ccr3.2871","article-title":"Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports","volume":"8","author":"Al-Janabi","year":"2020","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jid.2024.05.015_bib5","article-title":"Paradoxical psoriasis and worsening spondylitis due to secukinumab in a patient with ankylosing spondylitis: a case report and literature review","volume":"15","author":"Alnaqbi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2024.05.015_bib143","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/12034754231167140","article-title":"Brodalumab-induced eczematous reactions in psoriasis patients: management with switching to risankizumab","volume":"27","author":"Alsenaid","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jid.2024.05.015_bib6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jvc2.253","article-title":"Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab","volume":"2","author":"Anghel","year":"2023","journal-title":"JEADV Clin Pract"},{"key":"10.1016\/j.jid.2024.05.015_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/1756-185X.13791","article-title":"Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: case series","volume":"23","author":"Apaydin","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jid.2024.05.015_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2258240","article-title":"Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis","volume":"34","author":"Balakirski","year":"2023","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.05.015_bib9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1159\/000514952","article-title":"Pustular rash in Crohn\u2019s patient on ustekinumab raises concern for drug-induced paradoxical psoriasis","volume":"15","author":"Barahimi","year":"2021","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.jid.2024.05.015_bib121","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.annder.2021.02.003","article-title":"Dupilumab-induced psoriasis and alopecia areata: Case report and review of the literature","volume":"148","author":"Beaziz","year":"2021","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib144","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00296-018-4034-0","article-title":"Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn\u2019s disease-associated spondyloarthropathy","volume":"38","author":"Benzaquen","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2024.05.015_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2012.04.038","article-title":"Multiple-checkpoint inhibition of thymic stromal lymphopoietin-induced TH2 response by TH17-related cytokines","volume":"130","author":"Bogiatzi","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaci.2023.04.009","article-title":"The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2\/TH17 immune response","volume":"152","author":"B\u00f6hner","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib126","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"Helper 2 IL-4\/IL-13 Dual blockade with dupilumab is linked to some emergent t helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib104","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: a systematic review","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.jid.2024.05.015_bib13","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by Anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2024.05.015_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/tpj.2015.53","article-title":"Paradoxical psoriasiform reactions to Anti-TNF\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jid.2024.05.015_bib16","first-page":"202","article-title":"Successful management of ustekinumab-induced pustular psoriasis without therapy discontinuation","volume":"21","author":"Caca-Biljanovska","year":"2013","journal-title":"Acta Dermatovenerol Croat"},{"key":"10.1016\/j.jid.2024.05.015_bib115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/ajd.13846","article-title":"Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis","volume":"63","author":"Casale","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib17","article-title":"Paradoxical tumor necrosis factor-alpha (TNF-\u03b1) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment","volume":"15","author":"Chokshi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jid.2024.05.015_bib108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1346-8138.16595","article-title":"Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis","volume":"50","author":"Chromy","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.05.015_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2024.05.015_bib134","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15084","article-title":"Paradoxical psoriasis induced by anti-TNF-alpha successfully treated with brodalumab","volume":"34","author":"Cortonesi","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2022.06.019","article-title":"Predictors of severity in paradoxical psoriasis from biologic therapies: a systematic review","volume":"88","author":"Croitoru","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/03009742.2019.1594359","article-title":"New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report","volume":"49","author":"Currado","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jid.2024.05.015_bib21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/pde.14712","article-title":"Paradoxical psoriasis in pediatric patients: a systematic review","volume":"38","author":"Cyrenne","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib148","first-page":"176","article-title":"Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab","volume":"116","author":"Dai","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jid.2024.05.015_bib120","article-title":"Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: Clinical and dermoscopic patterns","volume":"33","author":"D\u2019Ambra","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib23","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.14309\/crj.2018.47","article-title":"Development of drug-induced inverse psoriasis in a patient with Crohn\u2019s disease","volume":"5","author":"Darwin","year":"2018","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.jid.2024.05.015_bib141","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/ajd.14142","article-title":"Palmoplantar pustulosis successfully treated with upadacitinib: Report of three cases","volume":"64","author":"Gaiani","year":"2023","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib150","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/DER.0000000000000570","article-title":"Psoriatic plaques afterinitiation of dupilumab therapy","volume":"31","author":"DeGrazia","year":"2020","journal-title":"Dermatitis"},{"key":"10.1016\/j.jid.2024.05.015_bib25","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1111\/jdv.16293","article-title":"Baricitinib-induced paradoxical psoriasis","volume":"34","author":"Di Domizio","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ced.13731","article-title":"Secukinumab-induced paradoxical pustular psoriasis","volume":"44","author":"Dogra","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13504","article-title":"Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient","volume":"33","author":"Durmaz","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib28","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","article-title":"Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor \u03b1 Inhibitors","volume":"159","author":"Eickstaedt","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/09546634.2020.1782816","article-title":"Secukinumab retreatment associated psoriasis flare with pustules","volume":"33","author":"El-Komy","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.05.015_bib30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.46497\/ArchRheumatol.2020.7541","article-title":"Tofacitinib induced psoriasiform lesion in a patient with rheumatoid arthritis","volume":"35","author":"Erol","year":"2020","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.jid.2024.05.015_bib102","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib31","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/jdv.19561","article-title":"Iatrogenic switch from psoriasis to eczema: what does it mean and is it predictable?","volume":"37","author":"Eyerich","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1104200","article-title":"Mutual antagonism of T cells causing psoriasis and atopic eczema","volume":"365","author":"Eyerich","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.05.015_bib33","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/all.15741","article-title":"Age of onset defines two distinct profiles of atopic dermatitis in adults","volume":"78","author":"Facheris","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jid.2024.05.015_bib123","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15345","article-title":"A case of dupilumab-induced reverse psoriasis in a patient with atopic dermatitis","volume":"35","author":"Fan","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/cjp2.147","article-title":"Paradoxical psoriasis induced by TNF-\u03b1 blockade shows immunological features typical of the early phase of psoriasis development","volume":"6","author":"Fania","year":"2020","journal-title":"J\u00a0Pathol Clin Res"},{"key":"10.1016\/j.jid.2024.05.015_bib35","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/ced.15104","article-title":"Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib","volume":"47","author":"Ferrucci","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib131","doi-asserted-by":"crossref","first-page":"1256133","DOI":"10.3389\/fimmu.2023.1256133","article-title":"IL-17A-driven psoriasis is critically dependent on IL-36 signaling","volume":"14","author":"Fischer","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib36","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/MIB.0000000000000198","article-title":"IL-36\u03b3 sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease","volume":"20","author":"Friedrich","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2024.05.015_bib37","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","article-title":"Management of patients affected by moderate-to-severe atopic dermatitis with JAK inhibitors in real-world clinical practice: an Italian Delphi consensus","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2024.05.015_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2183729","article-title":"Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series","volume":"34","author":"Gargiulo","year":"2023","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.05.015_bib135","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s13555-021-00672-z","article-title":"Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in a patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab","volume":"12","author":"Gkalpakiotis","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jid.2024.05.015_bib40","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1084\/jem.20101102","article-title":"Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons","volume":"207","author":"Gregorio","year":"2010","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2024.05.015_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1684\/ejd.2011.1164","article-title":"Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis","volume":"21","author":"Gregoriou","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib42","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jid.2022.10.015","article-title":"IL-4\/IL-13 inhibitors for atopic dermatitis induce psoriatic rash transcriptionally close to pustular psoriasis","volume":"143","author":"Grolleau","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib43","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study","volume":"22","author":"Guerra","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2024.05.015_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2017.08.008","article-title":"Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?","volume":"48","author":"Guttman-Yassky","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib45","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/ced.12392","article-title":"Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy","volume":"39","author":"Hay","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib47","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/ced.14757","article-title":"Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab","volume":"46","author":"Hlaca","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib48","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1111\/1346-8138.15082","article-title":"Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab","volume":"46","author":"Honma","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib49","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/ced.13375","article-title":"Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab","volume":"43","author":"Hoshina","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib50","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/1346-8138.14842","article-title":"Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction","volume":"46","author":"Hosokawa","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib122","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15399","article-title":"De novo pustular psoriasis associated with dupilumab therapy in a young male with the diagnosis of atopic dermatitis","volume":"35","author":"Incel Uysal","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib51","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/jdv.17050","article-title":"De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort","volume":"35","author":"Jaulent","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib52","doi-asserted-by":"crossref","first-page":"E5825","DOI":"10.1073\/pnas.1509971112","article-title":"I\u03baB\u03b6 is a key driver in the development of psoriasis","volume":"112","author":"Johansen","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.05.015_bib132","first-page":"168","article-title":"Treatment of anti-TNF-related paradoxic palmoplantar psoriasis in Beh\u00e7et\u2019s disease with azathioprine","volume":"37","author":"Karadeniz","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2024.05.015_bib106","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/medicina60010106","article-title":"Paradoxical psoriasis induced by ustekinumab: a comprehensive review and case report","volume":"60","author":"Klimko","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jid.2024.05.015_bib53","article-title":"Palmoplantar pustulosis-like eruption induced by baricitinib for treatment of rheumatoid arthritis","volume":"7","author":"Koumaki","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.jid.2024.05.015_bib147","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1684\/ejd.2021.4140","article-title":"Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment","volume":"31","author":"Kurihara","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib54","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5021\/ad.2017.29.6.794","article-title":"Paradoxical flare of psoriasis after ustekinumab therapy","volume":"29","author":"Lee","year":"2017","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib124","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/pde.15497","article-title":"Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients","volume":"41","author":"Lockard","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib55","article-title":"Paradoxical psoriasis: the flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?","volume":"7","author":"Lu","year":"2023","journal-title":"J\u00a0Transl Autoimmun"},{"key":"10.1016\/j.jid.2024.05.015_bib119","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.abd.2021.03.005","article-title":"Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis","volume":"96","author":"Maiolini","year":"2021","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib109","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/1346-8138.17085","article-title":"Psoriasis-like lesions in an atopic dermatitis patient possibly associated with nemolizumab treatment","volume":"51","author":"Masuda","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib139","first-page":"69","article-title":"Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn\u2019s disease","volume":"12","author":"Matsumoto","year":"2018","journal-title":"Biologics"},{"key":"10.1016\/j.jid.2024.05.015_bib105","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-\u03b1 inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib56","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaci.2022.04.027","article-title":"Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis","volume":"150","author":"McCluskey","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib107","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/ced.15006","article-title":"Risankizumab-induced paradoxical pustular psoriasis","volume":"47","author":"McFeely","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib142","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000513467","article-title":"Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of Psoriasis","volume":"13","author":"Mendes Roncada","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib57","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjd.20064","article-title":"Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report","volume":"185","author":"Mirza","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib58","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jid.2019.10.010","article-title":"Enrichment of polyfunctional IL-17-producing T cells in paradoxical psoriasis skin lesions","volume":"140","author":"Moran","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib59","article-title":"Paradoxical palmoplantar pustulosis induced by secukinumab and Brodalumab: a report of three cases","author":"M\u00f6ssner","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib60","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/all.15921","article-title":"Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the \"Flip-Flop\" phenomenon)","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jid.2024.05.015_bib103","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/09546634.2016.1230173","article-title":"Eczema as an adverse effect of Anti-TNF\u03b1 therapy in psoriasis and other Th1-mediated diseases: a review","volume":"28","author":"Nakamura","year":"2017","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.05.015_bib63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bjd.19459","article-title":"Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment","volume":"184","author":"Napolitano","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/ced\/llae162","article-title":"Efficacy of JAK inhibitors in the treatment of psoriasiform atopic dermatitis","author":"Napolitano","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ced\/llad390","article-title":"Dupilumab-associated inflammatory arthritis: a literature review","volume":"49","author":"Napolitano","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib114","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib127","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/annrheumdis-2021-eular.1363","article-title":"AB0573 Dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study","volume":"80","author":"Nathan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2024.05.015_bib66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cup.14113","article-title":"Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents","volume":"49","author":"Navarro","year":"2022","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jid.2024.05.015_bib67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2024.05.015_bib68","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41590-022-01339-3","article-title":"IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation","volume":"23","author":"Ni","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12505","article-title":"Anti IL-17 flared psoriasis in a patient on secukinumab","volume":"30","author":"Noell","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib71","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000342503","article-title":"Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature","volume":"225","author":"Os\u00f3rio","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2024.05.015_bib72","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.05.015_bib73","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/pde.14820","article-title":"Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children","volume":"38","author":"Parker","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15788","article-title":"Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib","volume":"35","author":"Patruno","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib74","first-page":"106","article-title":"Palmoplantar pustulosis under secukinumab in two patients without psoriasis","volume":"20","author":"Penalba-Torres","year":"2022","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2024.05.015_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2024.05.015_bib77","first-page":"10","article-title":"Two cases of anti-interleukin-17 flared psoriasis","volume":"79","author":"Prussick","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib110","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib116","doi-asserted-by":"crossref","first-page":"e1432","DOI":"10.1111\/jdv.19351","article-title":"Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis","volume":"37","author":"Quattrini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2022.2133533","article-title":"Systematic review of TNF\u03b1-induced paradoxical psoriasis: treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients","volume":"34","author":"Revankar","year":"2023","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.05.015_bib80","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1111\/ced.13901","article-title":"Psoriasis induced by dupilumab therapy","volume":"44","author":"Safa","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib82","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3794","article-title":"DNA copy number variation associated with anti-tumour necrosis factor drug response and paradoxical psoriasiform reactions in patients with moderate-to-severe psoriasis","volume":"101","author":"Sanz-Garcia","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2024.05.015_bib128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjd.19631","article-title":"Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated","volume":"184","author":"Sears","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib83","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jdcr.2019.03.024","article-title":"Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis","volume":"5","author":"Shibata","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.05.015_bib84","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.05.015_bib85","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jamadermatol.2017.2826","article-title":"Secukinumab-induced psoriasiform eruption","volume":"153","author":"Sladden","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib86","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.dsi.2016.10.002","article-title":"Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab","volume":"35","author":"Su","year":"2017","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.jid.2024.05.015_bib113","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2024.05.015_bib87","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/1346-8138.13803","article-title":"Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy","volume":"45","author":"Suh","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib88","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/cup.13952","article-title":"Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy","volume":"48","author":"Tan","year":"2021","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.jid.2024.05.015_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130078","article-title":"Methotrexate is a JAK\/STAT pathway inhibitor","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2024.05.015_bib136","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5114\/ada.2019.87454","article-title":"Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab","volume":"36","author":"Tichy","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jid.2024.05.015_bib89","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jid.2024.05.015_bib90","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jdcr.2018.05.014","article-title":"Erythrodermic presentation of psoriasis in a patient treated with dupilumab","volume":"4","author":"Tracey","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2024.05.015_bib91","first-page":"6291","article-title":"\"De novo\" psoriasis and relapse of psoriasis induced by dupilumab: three new cases and review of the literature","volume":"12","author":"Trave","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jid.2024.05.015_bib137","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1159\/000533370","article-title":"Adalimumab-induced paradoxical psoriasis treated with biologics targeting the IL-17\/IL-23 axis in patients with hidradenitis suppurativa","volume":"239","author":"Tsiogka","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2024.05.015_bib92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4274\/turkderm.galenos.2022.39591","article-title":"Secukinumab-induced paradoxical palmoplantar pustular psoriasis","volume":"56","author":"\u00dcr\u00fcn","year":"2022","journal-title":"TURKDERM"},{"key":"10.1016\/j.jid.2024.05.015_bib93","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/09546634.2010.534430","article-title":"Flare of pustular psoriasis after initiating ustekinumab therapy","volume":"23","author":"Wenk","year":"2012","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2024.05.015_bib94","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib140","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.36849\/JDD.7645","article-title":"A case series of TNF inhibitor-induced psoriasis successfully treated with upadacitinib","volume":"23","author":"Woodbury","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib95","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40257-023-00804-5","article-title":"Dupilumab-associated arthritis: a dermatology-rheumatology perspective","volume":"24","author":"Woodbury","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib96","article-title":"Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib97","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1093\/rheumatology\/kead318","article-title":"The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study","volume":"62","author":"Yagiz","year":"2023","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.jid.2024.05.015_bib146","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"42","author":"Yang","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jid.2024.05.015_bib98","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4049\/jimmunol.0901706","article-title":"Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation","volume":"184","author":"Yu","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib151","first-page":"311","article-title":"Pustular psoriasis appearing induced by dupilumab therapy in a patient with atopic dermatitis","volume":"21","author":"Jia","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jid.2024.05.015_bib152","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15713","article-title":"Recalcitrant and persistent adalimumab-induced paradoxical psoriasiform skin reaction in a rheumatoid arthritis patient successfully treated with upadacitinib","volume":"35","author":"Zabotti","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib100","article-title":"Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.05.015_bib133","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13132","article-title":"Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis","volume":"32","author":"Zheng","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2024.05.015_bib101","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/all.16019","article-title":"Efficacy of dupilumab in palmoplantar pustulosis treatment highlights the role of Th2 inflammation","volume":"79","author":"Zheng","year":"2024","journal-title":"Allergy"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24017317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24017317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:42:41Z","timestamp":1762029761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24017317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0022202X24017317"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.05.015","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}